Literature DB >> 11709303

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.

A H Groll1, D Mickiene, V Petraitis, R Petraitiene, K H Ibrahim, S C Piscitelli, I Bekersky, T J Walsh.   

Abstract

The plasma pharmacokinetics and tissue distribution of the novel antifungal echinocandin-like lipopeptide micafungin (FK463) were investigated in healthy rabbits. Cohorts of three animals each received micafungin at 0.5, 1, and 2 mg/kg of body weight intravenously once daily for a total of 8 days. Serial plasma samples were collected on days 1 and 7, and tissue samples were obtained 30 min after the eighth dose. Drug concentrations were determined by validated high-performance liquid chromatographic methods. Plasma drug concentration data were fit to a two-compartment pharmacokinetic model, and pharmacokinetic parameters were estimated using weighted nonlinear least-square regression analysis. Micafungin demonstrated linear plasma pharmacokinetics without changes in total clearance and dose-normalized area under the concentration-time curve from 0 h to infinity. After administration of single doses to the rabbits, mean peak plasma drug concentrations ranged from 7.62 microg/ml at 0.5 mg/kg to 16.8 microg/ml at 2 mg/kg, the area under the concentration-time curve from 0 to 24 h ranged from 5.66 to 21.79 microg x h/ml, the apparent volume of distribution at steady state ranged from 0.296 to 0.343 liter/kg, and the elimination half-life ranged from 2.97 to 3.20 h, respectively. No significant changes in pharmacokinetic parameters and no accumulation was noted after multiple dosing. Mean tissue micafungin concentrations 30 min after the last of eight daily doses were highest in the lung (2.26 to 11.76 microg/g), liver (2.05 to 8.82 microg/g), spleen (1.87 to 9.05 microg/g), and kidney (1.40 to 6.12 microg/g). While micafungin was not detectable in cerebrospinal fluid, the concentration in brain tissue ranged from 0.08 to 0.18 microg/g. These findings indicate linear disposition of micafungin at dosages of 0.5 to 2 mg/kg and achievement of potentially therapeutic drug concentrations in plasma and tissues that are common sites of invasive fungal infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709303      PMCID: PMC90832          DOI: 10.1128/AAC.45.12.3322-3327.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.

Authors:  A H Groll; B M Gullick; R Petraitiene; V Petraitis; M Candelario; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Authors:  S Matsumoto; Y Wakai; T Nakai; K Hatano; T Ushitani; F Ikeda; S Tawara; T Goto; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.

Authors:  K Uchida; Y Nishiyama; N Yokota; H Yamaguchi
Journal:  J Antibiot (Tokyo)       Date:  2000-10       Impact factor: 2.649

5.  In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

Authors:  H Mikamo; Y Sato; T Tamaya
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

6.  Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.

Authors:  S Maesaki; M A Hossain; Y Miyazaki; K Tomono; T Tashiro; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Authors:  A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

8.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 10.  Antibiotics that inhibit fungal cell wall development.

Authors:  M Debono; R S Gordee
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

View more
  40 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  Human tissue distribution of voriconazole.

Authors:  Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Authors:  Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

Review 4.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 5.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

6.  Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.

Authors:  Shuai Shi; Elizabeth S Dodds Ashley; Barbara D Alexander; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2009-02-03       Impact factor: 3.246

Review 7.  Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.

Authors:  Carlo Tascini; Maria Grazia Bongiorni; Enrico Tagliaferri; Antonello Di Paolo; Sarah Flammini; Ezio Soldati; Alessandro Leonildi; Andrea Di Cori; Francesco Menichetti
Journal:  Mycopathologia       Date:  2012-10-17       Impact factor: 2.574

Review 8.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid.

Authors:  Asma Lat; George R Thompson; Michael G Rinaldi; Sheryl A Dorsey; Gennethel Pennick; James S Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

10.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.